Landmark UK legislation improves access to personalised therapies
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has brought in new regulations designed to make it easier for personalised cancer treatments and gene therapies to be made where patients are treated.
The new legislation ‘The Human Medicines (Amendment) (Modular Manufacture and Point of Care) Regulations 2025’ was created to ensure patients can receive treatments made at their hospital, clinic or near their homes instead of waiting weeks for therapies manufactured hundreds of miles away.
The world first regulations allow personalised medicines like CAR-T therapy to be prepared in small or individual batches – bringing care closer to the patient.
According to the MHRA, a cancer patient could now have their immune cells collected, modified to fight their specific cancer, and returned within days rather than months.
The Agency says the change will cut waiting times, help free up NHS beds, and improve access to innovative therapies.
Quicker access to cell & gene therapies
MHRA Chief Executive Lawrence Tallon said: “Patients will now receive highly personalised treatments more quickly and nearer to their bedside, with the same rigorous standards as all medicines. This is especially important where every hour matters, or where a treatment is so specific it simply can’t be made in advance. It’s a landmark moment that opens the door to a future where highly personalised treatment – made for one person, in one place, at one time – becomes part of routine care.”
The legislation also supports the use of mobile manufacturing units – offering a safer alternative for patients too unwell to travel, or whose weakened immune systems mean hospital visits carry extra risk.
It covers a broad range of innovative products, including cell and gene therapies, tissue-engineered treatments, 3D printed products, blood products, and medicinal gases.
Cell and Gene Therapy Catapult Chief Executive Matthew Durdy said: “This is not just a step forward for innovative medicines such as cell and gene therapies, it is a step towards enabling truly personalised medicine. We applaud this change introduced by the MHRA and look forward to a future where more patients can receive therapeutics tailored to their needs, quickly, cost-effectively and sustainably.”
Diana Turner, Senior Digital Content Editor, DDW
